The addition of 20,000 sq. ft. of manufacturing and office space increases Avecia’s Milford, Ma, oligonucleotide capacity to 3.0 mol.
Nitto Denko Avecia Inc. (Avecia) announced on July 13, 2017 that the company will open a new oligonucleotide API manufacturing facility in Milford, MA in August 2017. The expansion will add 20,000 sq. ft. of manufacturing and office space at the site and provide CGMP oligonucleotide manufacturing capacity up to 1.8 mol, bringing the site capacity to 3.0 mol.
The company reported that it has added more than 120 jobs in Massachusetts in the past 12 months in Milford and currently has more than 50 open positions in microbiology, analytical chemistry, manufacturing, quality assurance, and engineering at its four locations in Massachusetts, Ohio, and California.
“This expansion will help Avecia’s clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials as planned,” said Detlef Rethage, president of Avecia, in a July 13, 2017 press statement. “Avecia takes pride that our engineers have introduced novel technology, executed this expansion in record time, and in close collaboration with A/Z Corporation to ensure the timely supply of novel oligonucleotide therapeutics.”
An opening ceremony is scheduled for August 2017.
Source: Nitto Denko Avecia
INTERPHEX 2025: Critical Role of Walk-In Chambers in Bio/Pharma Development and Manufacturing
April 3rd 2025Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, sat down with the PharmTech Group at INTERPHEX 2025 to discuss the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.